MedTrace Logo

Screening in Primary Care of Advanced Liver Fibrosis in NAFLD And/or Alcoholic Patients

NCT05699018 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1788

Last updated 2025-01-23

No results posted yet for this study

Summary

The primary objective of the SOPRANO study is to compare two blood fibrosis tests, the eLIFT and the FibroMeter, for the screening of advanced liver fibrosis in patients with NAFLD and/or ALD from primary care centers.

Conditions

  • Non-alcoholic Fatty Liver Disease (NAFLD)
  • Alcoholic Liver Disease (ALD)
  • Liver Fibrosis

Interventions

DIAGNOSTIC_TEST

eLIFT

Diagnostic procedure: elastography devices, blood tests (e-LIFT + Fibrometer), liver biopsy if necessary (elastometry ≥ 8 kPa and \< 15 kPa)

Sponsors & Collaborators

  • University Hospital, Angers

    lead OTHER_GOV

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-13
Primary Completion
2025-12-13
Completion
2026-03-13

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05699018 on ClinicalTrials.gov